Quest PharmaTech Inc. (QPTFF)
| Market Cap | 2.44M -43.0% |
| Revenue (ttm) | n/a |
| Net Income | 3.68M |
| EPS | 0.02 |
| Shares Out | n/a |
| PE Ratio | 0.66 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,000 |
| Open | 0.0200 |
| Previous Close | n/a |
| Day's Range | 0.0200 - 0.0200 |
| 52-Week Range | 0.0200 - 0.0310 |
| Beta | -0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 22, 2026 |
About Quest PharmaTech
Quest PharmaTech Inc., a pharmaceutical company, develops targeted cancer therapies in Canada. Its lead product is MAb AR9.6, a theranostic agent for cancer in preclinical development for pancreatic cancer. The company is headquartered in Edmonton, Canada. [Read more]
News
Quest PharmaTech Provides Corporate Update including Voluntary Adoption of CSA Blanket Order 51-93 to File Financial Statements and MD&A on Semi-Annual Basis
EDMONTON, Alberta, May 29, 2026 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of...
Quest PharmaTech Announces Results from AGM
EDMONTON, Alberta, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”) today announced the results of its August 25, 2025 annual general meeting of sharehold...
Quest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTech
EDMONTON, Alberta, June 10, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality o...